Combining Growth Factor and Bone Marrow Cell Therapy Induces Bleeding and Alters Immune Response After Stroke in Mice | Zendy

JanKolja Strecker | Zendy; J. Olk | Zendy; Maike Hoppen | Zendy; Burkhard Gess | Zendy; Kai Diederich | Zendy; Antje Schmidt | Zendy; WolfRüdiger Schäbitz | Zendy; Matthias Schilling | Zendy; Jens Minnerup | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combining Growth Factor and Bone Marrow Cell Therapy Induces Bleeding and Alters Immune Response After Stroke in Mice

Author(s) -

JanKolja Strecker,

J. Olk,

Maike Hoppen,

Burkhard Gess,

Kai Diederich,

Antje Schmidt,

WolfRüdiger Schäbitz,

Matthias Schilling,

Jens Minnerup

Publication year - 2016

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.115.011230

Subject(s) - medicine , stroke (engine) , astrogliosis , immune system , inflammation , bone marrow , blood–brain barrier , immunology , pharmacology , central nervous system , mechanical engineering , engineering

Bone marrow cell (BMC)-based therapies, either the transplantation of exogenous cells or stimulation of endogenous cells by growth factors like the granulocyte colony-stimulating factor (G-CSF), are considered a promising means of treating stroke. In contrast to large preclinical evidence, however, a recent clinical stroke trial on G-CSF was neutral. We, therefore, aimed to investigate possible synergistic effects of co-administration of G-CSF and BMCs after experimental stroke in mice to enhance the efficacy compared with single treatments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research